Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Splenocytes from nonobese diabetic mice overexpressing murine IL (mIL)-4 upon recombinant retrovirus infection lose their capacity to transfer diabetes to nonobese diabetic-scid recipients. Diabetes appeared in 0-20% of mice injected with mIL-4-transduced cells vs 80-100% of controls injected with beta-galactosidase-transduced cells. Protected mice showed a majority of islets (60%) presenting with noninvasive peri-insulitis at variance with beta-galactosidase controls that exhibited invasive/destructive insulitis. Importantly, in all recipients, the transduced proteins were detected within islet infiltrates. Infiltrating lymphocytes from recipients of mIL-4-transduced cells produced high levels of mIL-4, as assessed by ELISA. In recipients of beta-galactosidase-transduced cells, approximately 60% of TCRalphabeta(+) islet-infiltrating cells expressed beta-galactosidase, as assessed by flow cytometry. The protection from disease transfer is due to a direct effect of mIL-4 gene therapy on immunoregulatory T cells rather than on diabetogenic cells. mIL-4-transduced purified CD62L(-) effector cells or transgenic BDC2.5 diabetogenic T cells still transferred disease efficiently. Conversely, mIL-4 transduction up-regulated the capacity of purified immunoregulatory CD62L(+) cells to inhibit disease transfer. These data open new perspectives for gene therapy in insulin-dependent diabetes using T cells devoid of any intrinsic diabetogenic potential.

Original publication

DOI

10.4049/jimmunol.166.8.4973

Type

Journal article

Journal

J immunol

Publication Date

15/04/2001

Volume

166

Pages

4973 - 4980

Keywords

Adjuvants, Immunologic, Adoptive Transfer, Animals, Cell Movement, Cells, Cultured, Clone Cells, Diabetes Mellitus, Type 1, Female, Genetic Therapy, Genetic Vectors, Immune Tolerance, Immunity, Active, Interleukin-4, Islets of Langerhans, L-Selectin, Lymphocyte Transfusion, Mice, Mice, Inbred NOD, Mice, SCID, Mice, Transgenic, Receptors, Antigen, T-Cell, alpha-beta, Retroviridae, Spleen, T-Lymphocyte Subsets, Transgenes, beta-Galactosidase